MetaCap

C4 Therapeutics Inc. (CCCC)

NASDAQ: CCCCHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

2.48+0.04 (+1.64%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CCCC stock chart

Technical analysis

Key statistics

All statistics
Market cap
$325.67M
EPS (TTM)
-$0.63
52-week range
1.69 – 5.17
Day range
2.32 – 2.55
Volume / Avg
3.63M / 2.57M
Beta
—

52-week range

$1.69$5.17

CCCC stock today

On Nov 20, CCCC ended the session at $2.48, adding $0.04 (1.64%), versus the S&P 500's 3.70% decline. At this level, CCCC sits in the middle of its 52-week range of $1.69 to $5.17: 52.0% below the high, set on Jun 30, 2026 and 46.7% above the low. CCCC is up 29.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 1.6%.

C4 Therapeutics has posted a net loss over the last twelve months (EPS of -$0.63), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About C4 Therapeutics

Company profile

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Andrew J. Hirsch M.B.A.
Headquarters
Watertown, MA
Employees
104
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, C4 Therapeutics generated $35.9 million in revenue, up 1.0% from fiscal 2024, its 2nd consecutive year of revenue growth. C4 Therapeutics reported a net loss of $105.0 million, compared with a loss of $105.3 million a year earlier. Operating margin was -320.5%.

C4 Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$35.95M$35.58M$20.76M$31.10M$45.78M
Growth+1.02%+71.44%-33.25%-32.08%—
Net income$-104.99M$-105.32M$-132.49M$-128.18M$-83.89M
EPS (diluted)$-1.27$-1.52$-2.67$-2.62$-1.82

Analyst forecast

Forecast

Consensus (9 analysts)

strong_buy

Avg. price target

$12.50+404.03%

  • Strong buy 2
  • Buy 7
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $6.00High $30.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.16 vs $-0.20
Surprise
+20.00%

CCCC news

All CCCC news

C4 Therapeutics peers

Health Care sector
CCCC peer companies
CompanyPrice% ChgMarket capCompare
SLBTSL Science Holding Limited0.55-3.36%$308.42Mvs CCCC
XFORX4 Pharmaceuticals Inc.3.00+1.35%$306.34Mvs CCCC
TRXBTRex Bio Inc.10.32+6.12%$296.95Mvs CCCC
ALECAlector Inc.2.34+1.52%$347.63Mvs CCCC
DTILPrecision BioSciences Inc.7.40+7.09%$282.46Mvs CCCC
AGENAgenus Inc.5.97-2.77%$270.12Mvs CCCC
KYTXKyverna Therapeutics Inc.4.26-2.52%$269.33Mvs CCCC
AGMBAgomAb Therapeutics NV ADR5.45-3.02%$268.40Mvs CCCC

Indexes, lists and sector

C4 Therapeutics stock FAQ

What is C4 Therapeutics's stock price today?

CCCC last traded at $2.48 as of Nov 20, 4:00 PM EST, up 1.64% on the day. Prices are delayed at least 15 minutes.

Who is C4 Therapeutics's CEO?

Mr. Andrew J. Hirsch M.B.A. is the chief executive officer of C4 Therapeutics Inc., which has about 104 employees.

What is the CCCC 52-week high?

The 52-week high for CCCC is $5.17 and the 52-week low is $1.69. The stock is currently 52.0% below its high.

Compare CCCC